Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | BA3021 |
Trade Name | |
Synonyms | CAB-ROR2-ADC|BA 3021|Ozuriftamab Vedotin |
Drug Descriptions |
BA3021 (CAB-ROR2-ADC) is a conditionally active anti-ROR2 antibody in conjugation with a cytotoxic agent that preferentially binds and delivers cytotoxicity to Ror2-expressing cells in tumors, which potentially induces antitumor activity (Cancer Res (2018) 78 (13_Supplement): 833). |
DrugClasses | |
CAS Registry Number | 2460400-11-5 |
NCIT ID | C155812 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
BA3021 | BA3021 | 0 | 2 |
BA3021 + Durvalumab | BA3021 Durvalumab | 0 | 1 |